Astal Laboratories Receives Substantial Acquisition Disclosure for 48.67 Lakh Shares Through Preferential Allotment

Astal laboratories has disclosed a substantial share acquisition by investor Sesha Sai Nikhil Chintalapati through preferential allotment. The company received the mandatory disclosure under SEBI regulations on January 19, 2026, regarding the significant increase in shareholding by the non-promoter investor.

Share Acquisition Details

Sesha Sai Nikhil Chintalapati acquired 48,67,348 equity shares on January 14, 2026, through preferential allotment pursuant to a share swap arrangement. The acquisition represents a substantial increase in his stake in the pharmaceutical company.

Parameter	Before Acquisition	After Acquisition	Change
Shares Held	1,17,930	49,85,278	+48,67,348
Voting Capital %	1.09%	11.81%	+10.72%
Diluted Capital %	0.87%	11.33%	+10.46%

Regulatory Compliance

The disclosure was made pursuant to Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Chintalapati belongs to the non-promoter group of Astal Laboratories Limited and submitted the required documentation to both BSE Limited and the company on January 16, 2026.

The transaction involved persons acting in concert, including Venkata Ramchandra Murthy Chintalapati, who maintained his existing holding of 2,507 shares (0.01% of voting capital) without any changes during this acquisition.

Impact on Share Capital Structure

The preferential allotment significantly altered the company's equity structure:

Capital Structure	Before Transaction	After Transaction
Equity Share Capital	₹10.77 crores	₹42.22 crores
Number of Shares	1,07,70,000	4,22,15,632
Diluted Share Capital	Not specified	₹43.99 crores
Diluted Shares Count	Not specified	4,39,85,632

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.14%	-0.48%	+0.21%	-11.68%	+17.78%	+887.43%

Transaction Details

The share acquisition significantly increased Harish's stake in the pharmaceutical company. The transaction details are presented below:

Parameter:	Before Acquisition	After Acquisition
Number of Shares:	1,17,000	28,15,140
Voting Capital %:	1.09%	6.67%
Diluted Capital %:	0.86%	6.40%

Acquisition Structure

The acquisition was executed through preferential allotment mechanism as part of a share swap transaction. Harish acquired 26,98,140 equity shares, representing 6.39% of the company's total share capital and 6.13% of diluted share capital. The investor belongs to the non-promoter group and had no encumbered shares or convertible securities before or after the transaction.

Company Capital Structure Changes

The transaction resulted in significant changes to Astal Laboratories' capital structure:

Capital Structure:	Amount	Number of Shares
Before Acquisition:	₹10.77 crores	1,07,70,000 shares
After Acquisition:	₹42.22 crores	4,22,15,632 shares
Total Diluted Capital:	₹43.99 crores	4,39,85,632 shares

All shares carry a face value of ₹10.00 each. The substantial increase in share capital indicates a significant corporate restructuring through the share swap mechanism.

Regulatory Compliance

The disclosure was made pursuant to Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Company Secretary Mahendra Kumar submitted the required documentation to BSE Limited on January 19, 2026. The company's shares are listed on BSE Limited under scrip code 512600 and security ID ASTALLTD.

Astal Laboratories Limited, formerly known as Macro International Limited, operates from its registered office in Noida, Uttar Pradesh, with corporate office located in Hyderabad, Telangana. The transaction represents a significant development in the company's shareholding pattern and demonstrates investor confidence in the pharmaceutical company's prospects.